RxDoctor Payments Data

Tristan Berry, MD

Urology · Tucson, AZNPI 1366572356

Payments from drug & device makers

What this record shows

This record is dominated by education: $12,000 of the $14,182 with a category attached, or 84.6%. Intuitive Surgical accounts for 87.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2020 at $12,719 and has fallen 99.4% since, to $74 in 2025.

$14,182in general payments, 2019–2025

Across 60 payments — averaging $236.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$12K
  • Angiodynamics, Inc.$447
  • Boston Scientific$226
  • Teleflex LLC$179
  • Coloplast$159
  • Axonics, Inc.$139
  • plus $581 from 16 others

What the payments were for

  • Travel & lodging$1711%
  • Food & beverage$2,01114%
  • Education$12,00085%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,182 in reported general payments places this provider in the 80th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$90,084
Medicare patients
293
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron35$29,238
MyrbetriqMirabegron18$22,111
Tolterodine Tartrate ErTolterodine Tartrate76$4,633
Silodosin49$3,729
Tamsulosin Hcl227$3,214
Testosterone17$3,167
Darifenacin ErDarifenacin Hydrobromide24$2,680
Oxybutynin Chloride ErOxybutynin Chloride27$1,050
Solifenacin Succinate19$965
Tolterodine Tartrate11$614
Finasteride53$557
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$551
Terazosin Hcl16$340
Cephalexin19$236
Ciprofloxacin Hcl40$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$28$29,23835 claims
Astellas Pharma US IncMyrbetriq$31$22,11118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 269 urology providers in Arizona.

Other urology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →